Is Gossamer Bio, Inc. (GOSS) a Buy, Sell, or Hold?
Gossamer Bio, Inc.
NASDAQ:GOSS
$0.1617 USD
$0.02 (15.42%)
- Volume
- 24.52M
- Average Volume
- 12.61M
- Market Capitalization
- $37.93M
- P/E Ratio
- -0.20
- Dividend Yield
- 0.00%
- Price Target
- $1.00
- Year High
- $3.87
- Year Low
- $0.11
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.20
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Faheem Hasnain |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GOSS |
| CUSIP | 38341P102 |
| CIK | 0001728117 |
| Web | https://www.gossamerbio.com |
| Phone | 858 684 1300 |
| Currency | USD |
| Employees | 162 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -1.26 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.20 |
| Quick Ratio | 2.20 |
| Cash Ratio | 0.73 |
Sales & Book Value
| Annual Sales | $48.47M |
| Price / Sales | 0.68 |
| Cash Flow | -0.73 |
| Price / Cash Flow | -0.22 |
| Price / Book | -0.23 |
Price Target and Rating
| Average Stock Price Forecast | $1.00 |
| High Stock Price Forecast | $1.00 |
| Low Stock Price Forecast | $0.30 |
| Forecast Upside/Downside | -83.83% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 17 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.75 |
| Trailing P/E Ratio | -0.20 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-170.37M |
| Net Margin | -324.82% |
| Pretax Margin | -324.98% |
| Return on Equity | 174.85% |
| Return on Assets | -139.95% |
Financials Score
| AltmanZ Score | -19.35 |
| Piotroski Score | 1.00 |
| Working Capital | 68.03M |
| Total Assets | 128.9M |
| Ebit | -169.49M |
| Market Cap | 31.31M |
| Total Liabilities | 290.38M |
Poll Results
About Gossamer Bio, Inc. (NASDAQ:GOSS) Stock
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California. ...
2026-07-01 09:00:00
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 (the “2030 Convertible Notes”) will be 5,347.5936 shares of t.
2026-06-17 08:00:00
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the final tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 202.
2026-06-03 08:00:00
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the early tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 202.
2026-06-02 08:00:00
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has extended the early tender date (as extended, the “Extended Early Tender Date”) until 5:00 p.m., New York City time, on June 2, 2026 with respect to.
2026-06-01 13:00:00
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (âGossamerâ or the â
2026-06-01 12:38:00
NEW YORK--(BUSINESS WIRE)---- $GOSS #Bio--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has.
2026-06-01 12:00:00
New York, New York--(Newsfile Corp. - June 1, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
2026-06-01 12:00:00
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026, both dates inclusive (the “Class Period”).
Frequently Asked Questions
-
What is the current Gossamer Bio, Inc. (GOSS) stock price?
-
Gossamer Bio, Inc.(NASDAQ:GOSS) stock price is $0.1617 in the last trading session. During the trading session, GOSS stock reached the peak price of $3.87 while $0.114 was the lowest point it dropped to. The percentage change in GOSS stock occurred in the recent session was 15.42% while the dollar amount for the price change in GOSS stock was $0.02.
-
GOSS's industry and sector of operation?
-
The NASDAQ listed GOSS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GOSS?
-
Richard Aranda | Chief Medical Officer
Kelly Dawson | Senior Vice President of Program Team Lead
Bryan Giraudo | Chief Operating Officer & Chief Financial Officer
Christian Waage | Executive VP, General Counsel & Secretary
Robert Smith | Chief Commercial Officer -
How many employees does GOSS have?
-
Number of GOSS employees currently stands at 162. GOSS operates from 3115 Merryfield Row, San Diego, CA 92121, US.
-
Link for GOSS official website?
-
Official Website of GOSS is: https://www.gossamerbio.com
-
How do I contact GOSS?
-
GOSS could be contacted at phone #858 684 1300 and can also be accessed through its website. GOSS operates from 3115 Merryfield Row, San Diego, CA 92121, US.
-
How many shares of GOSS are traded daily?
-
The average number of GOSS shares traded daily for last 3 months was 12.61M.
-
What is the market cap of GOSS currently?
-
The market value of GOSS currently stands at $37.93M with its latest stock price at $0.1617